CMG Pharmaceutical Co. Ltd (058820.KQ) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · South Korea · ISIN KR7058820002

Price
4,200.00 KRW
Market cap
62.09 bn KRW
P/E (2025)
–
P/S (2025)
0.59
Dividend yield
0.00 %
Net margin
-9.58 %
Return on equity (ROE)
-5.00 %
Return on assets (ROA)
-3.29 %

CMG Pharmaceutical Co. Ltd financials

Fiscal year20242025
Revenue99.10 bn KRW105.23 bn KRW
Gross profit45.72 bn KRW60.93 bn KRW
Operating income2.51 bn KRW-3.69 bn KRW
EBIT5.39 bn KRW-8.67 bn KRW
Net income2.69 bn KRW-10.08 bn KRW
Diluted EPS – continuing operations19.40 KRW-68.16 KRW

Full history since 2011, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About CMG Pharmaceutical Co. Ltd

CMG Pharmaceutical Co., Ltd., a pharmaceutical company, develops and sells oral thin film (OTF) pharmaceuticals in South Korea. It offers Tadalafil OTF products for erectile dysfunction; Entecavir OTF products to treat hepatitis type B; Aripiprazole OTF products for schizophrenia; and Montelukast OTF products to treat asthma and allergic rhinitis. CMG Pharmaceutical Co. Ltd. has a strategic collaboration agreement with Handok Inc. for cancer treatment. The company was formerly known as Skynewpharm Co Ltd and changed its name to CMG Pharmaceutical CO., Ltd. in April 2013. CMG Pharmaceutical Co., Ltd. was founded in 2001 and is headquartered in Seoul, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.